

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 September 2005 (29.09.2005)

PCT

(10) International Publication Number
WO 2005/090330 A1

(51) International Patent Classification⁷: C07D 401/12,
413/12, 417/12, A61K 31/454, 31/445, A61P 3/04, 25/00

[SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(21) International Application Number:
PCT/SE2005/000411

(74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Södertälje (SE).

(22) International Filing Date: 21 March 2005 (21.03.2005)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
0400718-3 22 March 2004 (22.03.2004) SE
0402780-1 12 November 2004 (12.11.2004) SE


(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).
(72) Inventors; and
(75) Inventors/Applicants (for US only): BRICKMANN, Kay [DE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). EGNER, Bryan J. [GB/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). GIORDANETTO, Fabrizio [IT/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). INGHARDT, Tord [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINUSSON JONSSON, Anna [SE/SE]; Umeå University, Organic Chemistry, S-901 87 Umeå (SE). PONTEN, Fritiof

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: N-PIPERIDINE DERIVATES AS CCR3 MODULATORS



(57) Abstract: Compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

(I)

WO 2005/090330 A1